Mesoblast completes Phase 3 low back pain trial treatment as pivotal readout approaches
Mesoblast has completed treatment of 350 patients in its pivotal Phase 3 trial for chronic low back pain, with results expected in mid-2027.
Currently unlisted.
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Latest Threads
| Tag | Subject | ||||||
|---|---|---|---|---|---|---|---|
| JHC | Ann: Acquisition of Riviera Health Portfolio | 20/04/18 | 8 | 1.7K | |||
|
|||||||
| JHC | Ann: Update - Dividend/Distribution - JHC | 11:13 | 0 | 116 | |||
|
|||||||
| JHC | Ann: Completion of Riviera Health Acquisition | 03/04/18 | 0 | 96 | |||
|
|||||||
| JHC | Anyone else compared Estia/Regis/Japara ? | 17/03/18 | 4 | 1.1K | |||
|
|||||||
| JHC | Japara Potential | 10/03/18 | 15 | 3.3K | |||
|
|||||||
| JHC | update on investment potential | 10/03/18 | 8 | 1.7K | |||
|
|||||||
| JHC | Ann: Status Of Capital Refurbishment Deduction & Updated Guidance | 08/03/18 | 3 | 857 | |||
|
|||||||
| JHC | Ann: Capital Refurbishment Deductions | 07/03/18 | 2 | 439 | |||
|
|||||||
See All Discussions
ASX News